文献速递造血干细胞移植与细胞治疗

基于生物标志物的异基因造血干细胞移植患者非复发死亡风险实用监测模型

A pragmatic monitoring model for risk of non-relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem-cell transplantation.
PubMed 文献 · Br J Haematol · 2025-08-11

该前瞻性观察性多中心中国队列纳入619例异基因造血干细胞移植患者,在移植后3个月内多时间点检测ST2、REG3α、TNFR1、IL-6和IL-8,基于ST2与TNFR1近似最大浓度构建模型,在测试集和验证集AUC分别为0.85和0.95,可将验证集患者分为6个月NRM显著不同的高、中、低危组。

要点

  • 基于ST2与TNFR1近似最大浓度的模型在测试集AUC为0.85、验证集AUC为0.95,优于其他生物标志物组合模型。
  • 验证集按模型分为高、中、低危组,6个月NRM分别为47.37%、9.76%、0.0%(p<0.001)。
  • 采用统一阈值,模型在移植后第7、14、28天及aGVHD发生时均能将患者分为中高危与低危组,6个月NRM中高危组均高于低危组。

核心结论

  • 基于ST2与TNFR1近似最大浓度的模型可在多时间点灵活分层异基因造血干细胞移植患者的6个月非复发死亡风险,不限于特定时间点或临床特征,是临床适用的实用工具。

研究设计与样本

  • 前瞻性观察性多中心中国队列,纳入619例异基因造血干细胞移植患者,移植后3个月内多时间点检测ST2、REG3α、TNFR1、IL-6和IL-8。
  • 队列分为建模集(n=460,含训练/测试)和验证集(n=159)。

主要发现

  • 基于ST2与TNFR1近似最大浓度的模型在测试集AUC为0.85、验证集AUC为0.95,为其他生物标志物组合模型中最高的。
  • 验证集按模型分为高、中、低危组,6个月NRM分别为47.37%、9.76%、0.0%,组间差异显著(p<0.001)。
  • 采用统一阈值,模型在移植后第7、14、28天及aGVHD发生时均将患者分为中高危与低危组,6个月累积NRM中高危组分别为20.00%、33.33%、37.50%、30.77%,低危组分别为5.22%、5.22%、3.88%、7.14%。

关键数值与推荐

  • 模型基于ST2与TNFR1的近似最大浓度,测试集AUC=0.85、验证集AUC=0.95。
  • 验证集高危组6个月NRM为47.37%,中危组为9.76%,低危组为0.0%(p<0.001)。
  • 统一阈值下第7、14、28天及aGVHD发生时,中高危组6个月累积NRM分别为20.00%、33.33%、37.50%、30.77%,低危组分别为5.22%、5.22%、3.88%、7.14%。

临床怎么用

  • 该模型的应用不限于特定时间点或临床特征,可作为临床环境中灵活实用的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarkers predict non-relapse mortality (NRM) primarily driven by acute graft-versus-host disease (aGVHD) after allogeneic haematopoietic stem cell transplantation (allo-HSCT), yet existing single time point models lack clinical adaptability. In a prospective observational multicentre Chinese cohort of 619 allo-HSCT patients, serum concentrations of suppressor of tumorigenesis 2 (ST2), regenerating islet-derived 3α, tumour necrosis factor receptor 1 (TNFR1), interleukin-6 and interleukin-8 were measured at multiple time points during the first 3 months post-transplantation. Cohorts were divided into modelling (n = 460, training/test) and validation (n = 159) sets. A model based on the approximately maximum concentrations of ST2 and TNFR1 reached area under the curve of 0.85 and 0.95 in the test and validation cohorts, respectively, which was the highest among the models based on other biomarker panels. The model stratified validation cohort patients into high-risk (47.37%), moderate-risk (9.76%) and low-risk (0.0%) groups with significantly different 6-month NRM (p < 0.001). Using a universal threshold, the model consistently stratified patients into moderate-high-risk versus low-risk groups for NRM at all time points (days 7, 14, 28, aGVHD onset). Cumulative 6-month NRM was significantly higher in moderate-high-risk groups (20.00%, 33.33%, 37.50%, 30.77%) versus low-risk groups (5.22%, 5.22%, 3.88%, 7.14%). The application of this model is not confined to specific time points or clinical characteristics, rendering it a flexible and pragmatic tool in a clinical setting.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shao Y, Yang J, Li X, et al. A pragmatic monitoring model for risk of non-relapse mortality based on biomarkers in patients undergoing allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2025. PMID: 40789768. doi:10.1111/bjh.70070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。